Xeris Biopharma Holdings Form 144 Filed
A Form 144 for Xeris Biopharma Holdings was filed by Beth Hecht.
Related stories
FWD reports nine-month new business sales of $1.95B, up 1% year over year
M impact | EQUITY | Nov 02, 2026, 11:40 PM UTC
TETRA Technologies Reports Quarterly Results Through September 30
M impact | EQUITY | Nov 02, 2026, 11:39 PM UTC
Samsung Biologics Signs $324.8 Million Drug Manufacturing Contract
Samsung Biologics signed a drug manufacturing contract worth USD 324.8 million.
M impact | EQUITY | Nov 02, 2026, 11:37 PM UTC
Ero Copper Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 02, 2026, 11:36 PM UTC
PLDT Auditor SGV Resigns Over Independence Concerns
PLDT’s auditor, SyCip Gorres Velayo (SGV), resigned, citing a lack of independence.
M impact | EQUITY | Nov 02, 2026, 11:34 PM UTC
Argentine Stocks Fall for Sixth Straight Session as Country Risk Tops 800
Argentine shares fell for a sixth consecutive session, country risk exceeded 800 points and the central bank did not buy reserves.
M impact | EQUITY | Nov 02, 2026, 11:34 PM UTC